Regulation of the metastasis suppressor gene MKK4 in ovarian cancer

Gynecologic Oncology

Volumn 105, Issue 2, 2007, Pages 312-320

  Spillman, Monique A ^a   Lacy, Judith ^a   Murphy, Susan K ^a   Whitaker, Regina S ^a   Grace, Lisa ^a   Teaberry, Vanessa ^a   Marks, Jeffrey R ^a   Berchuck, Andrew ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

AKT; Metastasis; MKK4; Ovarian cancer

Indexed keywords

BISULFITE; CANCER GROWTH FACTOR; DNA; EPIDERMAL GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOSERINE; PROTEIN KINASE B; SERINE; WORTMANNIN;

ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL SURFACE; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE LOCUS; GENE SEQUENCE; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; METHYLATION; MKK4 GENE; OVARY CANCER; OVARY CELL; OVARY TUMOR; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPPRESSOR GENE; WESTERN BLOTTING;

BASE SEQUENCE; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; MAP KINASE KINASE 4; MAP KINASE SIGNALING SYSTEM; MOLECULAR SEQUENCE DATA; NEOPLASM STAGING; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROMOTER REGIONS (GENETICS);

EID: 34247128687     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.12.017     Document Type: Article

References (22)

1. McGuire W., Hoskins W., Brady M., Kucera P., Partridge E., Look K., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334 (1996) 1-5
2. Hoskins W., McGuire W., Brady M., Homesley H., Creasman W., Berman M., et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am. J. Obstet. Gynecol. 170 (1994) 974-979
3. Omura G., Brady M., Homesley H., Yordan E., Major F., Buchsbaum H., et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J. Clin. Oncol. 9 (1991) 1138-1150
4. Markman M., Bundy B., Alberts D., Fowler J., Clark-Pearson D., Carson L., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 19 (2001) 1001-1007
5. Berchuck A., Iversen E., Lancaster J., Dressman H., West M., Nevins J., et al. Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. Am. J. Obstet. Gynecol. 190 4 (2004) 910-925
6. Yamada S., Hickson J., Hrobowski Y., Vander Griend D., Benson D., Montag A., et al. Mitogen-activated protein kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma. Cancer Res. 62 (2002) 6717-6723
7. Yang D., Tournier C., Wysk M., Ku H.-T., Xu J., Davis R.J., et al. Targeted disruption of the MKK4 gene causes embryonic death, inhibition of c-Jun NH2-terminal kinase activation, and defects in AP-1 transcriptional activity. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 3004-3009
8. Robinson V., Hickson J., Vander Griend D., Dubauskas Z., and Rinker-Schaeffer C. MKK4 and metastasis suppression: a marriage of signal transduction and metastasis research. Clin. Exp. Metastasis 20 (2003) 25-30
9. Kim H., Vander Griend D., Yang X., Benson D., Dubauskas Z., Yoshida B., et al. Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression in inversely related to histological pattern in advancing human prostatic cancers. Cancer Res. 61 (2001) 2833-2837
10. Xin W., Yun K.J., Ricci F., Zahurak M., Qiu W., Su G.H., et al. MAP2K4/MKK4 expression in pancreatic cancer: genetic validation of immunohistochemistry and relationship to disease course. Clin. Cancer Res. 10 (2004) 8516-8520
11. Murphy S., and Jirtle R. Imprinted genes as potential genetic and epigenetic toxicologic targets. Environ. Health Perspect. 108 Suppl. 1 (2000) 5-11
12. Cuenda A. Mitogen-activated protein kinase kinase 4 (MKK4). International Journal of Biochemistry and Cell Biology 32 (2000) 581-587
13. Park H.-S., Kim M.-S., Huh S.-H., Park J., Chung J., Kang S., et al. Akt (protein kinase B) negatively regulates SEK1 by means of protein phosphorylation. J. Biol. Chem. 277 4 (2002) 2573-2578
14. Rodriguez G.C., Haisley C., Hurteau J., Moser T., Whitaker R., Bast R.J., et al. Regulation of invasion of epithelial ovarian cancer by transforming growth factor-beta. Gynecol. Oncol. 80 2 (2001) 245-253
15. Chae K.-S., Ryu B.-K., Lee M.-G., Byun D.-S., and Chi S.-G. Expression and mutation analyses of MKK4, a candidate tumour suppressor gene encoded by chromosome 17p, in human gastric adenocarcinoma. Eur. J. Cancer 38 (2002) 2048-2057
16. Su G., Hilgers W., Shekher M., Tang D., Yeo C., Hruban R., et al. Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. Cancer Res. 58 (1998) 2339-2342
17. Lee H.-Y., Srinivas H., Xia D., Lu Y., Superty R., LaPushin R., et al. Evidence that phosphatidylinositol 3-kinase and mitogen-activated protein kinase-4/c-Jun NH2-terminal kinase-dependent pathways cooperate to maintain lung cancer cell survival. J. Biol. Chem. 278 26 (2003) 23630-23638
18. Franke T., Hornik C., Segev L., Shostak G., and Sugimoto C. Pi3K/Akt and apoptosis: size matters. Oncogene 22 (2003) 8983-8998
19. Vander Griend D., Kocherginsky M., Hickson J., Stadler W., Lin A., and Rinker-Schaeffer C. Suppression of metastatic colonization by the context-dependent activation of the c-Jun NH2-terminal kinase kinases JNKK1/MKK4 and MKK7. Cancer Res. 65 23 (2005) 10984-10991
20. Steeg P. Metastasis suppressors alter the signal transduction of cancer cells. Nat. Rev., Cancer 3 (2003) 55-63
21. Cunningham S., Gallmeier E., Hucl T., Dezentje D., Calhoun E., Falco G., et al. Targeted deletion of MKK4 in cancer cells: a detrimental phenotype manifests as decreased experimental metastasis and suggests a counterweight to the evolution of tumor-suppressor loss. Cancer Res. 66 11 (2006) 5560-5564
22. Sawyers C. Will kinase inhibitors have a dark side?. N. Engl. J. Med. 355 (2006) 313-315